Drug Profile
Parenteral therapeutic - Accord Healthcare/Ferrer
Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator Accord Healthcare; Ferrer
- Developer Curia; Ferrer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Unspecified in Spain (Parenteral)
- 28 Mar 2021 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 21 Feb 2017 AMRI, Ferrer and Accord Healthcare agree to co-promote and co-develop parenteral therapeutic